Loar Holdings (NYSE:LOAR) 株価情報

Loar Holdings

Loar Holdings Inc in the design, manufacture, and sale of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Its manufactured products includes auto throttles, lap-belt airbags, two- and three-point seat belts, water purification systems, fire barriers, polyimide washers and bushings, latches, hold-open and tie rods, temperature and fluid sensors and switches, carbon and metallic brake discs, fluid and pneumatic-based ice protection, RAM air components, sealing solutions and motion and actuation devices, among others.

Loar Holdings Inc

UBS analyst John Lovallo maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and lowers the price target from $180 to $163.

News

Price Target

Analyst Ratings

BLDR

UBS Maintains Buy on Builders FirstSource, Lowers Price Target to $163

UBS analyst Joshua Spector maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and lowers the price target from $335 to $324.

UBS Maintains Buy on Air Products & Chemicals, Lowers Price Target to $324

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and lowers the price target from $355 to $310.

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310

UBS analyst Trung Huynh maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and lowers the price target from $319 to $315.

AMGN

UBS Maintains Neutral on Amgen, Lowers Price Target to $315

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 8.33% on an annualized basis producing an average annual return of 22.97%. Currently, Devon Energy has a market capitalization of $20.23 billion. 
Buying $100 In DVN: If an investor had bought $100 of DVN stock 5 years ago, it would be worth $275.31 today based on a price of $31.44 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Devon Energy 5 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

ALNY

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

UBS analyst Kevin Caliendo maintains Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Neutral and raises the price target from $16 to $17.

ALHC

UBS Maintains Neutral on Alignment Healthcare, Raises Price Target to $17

UBS analyst Joseph Spak maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Neutral and raises the price target from $58 to $66.

APTV

UBS Maintains Neutral on Aptiv, Raises Price Target to $66

UBS analyst Gavin Parsons maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Neutral and raises the price target from $120 to $155.

UBS Maintains Neutral on Howmet Aerospace, Raises Price Target to $155

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $21 to $22.

FOLD

UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22

UBS analyst Peter Grom maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and raises the price target from $60 to $62.

UBS Maintains Neutral on Estee Lauder Cos, Raises Price Target to $62

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $160 to $170.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $67 to $71.

UBS Maintains Neutral on CVS Health, Raises Price Target to $71

UBS analyst Eliana Merle maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $78 to $70.

MRNA

UBS Maintains Buy on Moderna, Lowers Price Target to $70

Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.45%. Currently, Casey's General Stores has a market capitalization of $16.70 billion. 
Buying $100 In CASY: If an investor had bought $100 of CASY stock 5 years ago, it would be worth $299.50 today based on a price of $458.65 for CASY at the time of writing.
<h3>Casey's General Stores's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASY

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $441 to $458.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $458

UBS analyst Joshua Spector maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Neutral and raises the price target from $21 to $22.

UBS Maintains Neutral on Olin, Raises Price Target to $22

UBS analyst Kevin Mcveigh maintains Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Neutral and raises the price target from $195 to $200.

PCTY

UBS Maintains Neutral on Paylocity Holding, Raises Price Target to $200

UBS analyst Trung Huynh maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and lowers the price target from $1100 to $1050.

UBS Maintains Buy on Eli Lilly, Lowers Price Target to $1050

UBS analyst Chris Kuntarich maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $400 to $500.

Comments

Loar Holdings

ニュース

パートナーシップ

ベンジンガ・グローバル